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Abstract
Glioblastoma multiforme (GBM) is the most common malignant primary brain cancer in adults; it carries a
dismal prognosis despite improvements in standard of care. We developed a combined gene therapy strategy
using (1) herpes simplex type 1-thymidine kinase in conjunction with the cytotoxic prodrug ganciclovir to kill
actively proliferating tumor cells and (2) doxycycline (DOX)-inducible Fms-like tyrosine kinase 3 ligand (Flt3L),
an immune stimulatory molecule that induces anti-GBM immunity. As a prelude to a phase I clinical trial, we
examined the efficacy and safety of this approach (Muhammad et al., 2010, 2012). In the present article, we
investigated the efficacy and safety of the ‘‘off-label’’ use of the antibiotic DOX to turn on the high-capacity
adenoviral vector (HC-Ad) encoding therapeutic Flt3L expression. DOX-inducible Flt3L expression in male Lewis
rats was assessed using DOX doses of 30.8mg/kg/day (low-DOX) or 46.2mg/kg/day (high-DOX), which are
allometrically equivalent (Voisin et al., 1990) to the human doses that are recommended for the treatment of
infections: 200 or 300mg/day. Naı¨ve rats were intracranially injected with 1· 109 viral particles of HC-Ad-TetOn-
Flt3L, and expression of the therapeutic transgene, that is, Flt3L, was assessed using immunohistochemistry in brain
sections after 2 weeks of DOX administration via oral gavage. The results show robust expression of Flt3L in the rat
brain parenchyma in areas near the injection site in both the low-DOX and the high-DOX groups, suggesting that
Flt3L will be expressed in human glioma patients at a DOX dose of 200 or 300mg/day. These doses have been
approved by the U.S. Food and Drug Administration to treat infections in humans and would thus be considered
safe for an off-label use to treat GBM patients undergoing HC-Ad-mediated gene therapy in a phase I clinical trial.
Introduction
Glioblastoma multiforme (GBM) is the most commonprimary brain tumor in adults, is highly invasive, and
has a median survival of *15–21 months (Grossman et al.,
2010). The current standard of care involves the resection of
the tumor mass with adjuvant radiotherapy and chemother-
apy; however, because of the highly infiltrative nature of
GBM, total tumor resection is virtually impossible and the
tumor invariably recurs. Tumor recurrence is associated with
novel mutations and genetic rearrangements, whichmakes its
treatment very challenging as patients with recurrent GBM
are generally unresponsive to chemotherapy and radiotherapy.
To develop a therapeutic approach for GBM that mediates
improved survival—including elimination of tumor cells that
infiltrate the brain parenchyma—we pursued a combined
conditional cytotoxic/immune-stimulatory gene therapy ap-
proach based on high-capacity, helper-dependent adenoviral
vectors (HC-Ad). We have performed rigorous preclinical
studies examining the efficacy and safety of the combined
HC-Ad-TK +HC-Ad-TetOn-Flt3L gene therapy in preclinical
models of intracranial GBM (Muhammad et al., 2010, 2012).
The implementation of this therapy in the clinic will in-
volve injection of both HC-Ads in the tumor bed after total
tumor resection, followed by systemic administration of
Valacyclovir, as the thymidine kinase (TK) prodrug (Fujita
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et al., 2006; Hinata et al., 2006; Shirakawa et al., 2007; Chiocca
et al., 2011), and doxycycline (DOX) as the transcriptional
activator of Fms-like tyrosine kinase 3 ligand (Flt3L) from the
TetOn promoter (Candolfi et al., 2006; Xiong et al., 2006;
Curtin et al., 2008b; Muhammad et al., 2010, 2012). Im-
portantly, the DOX-regulatable expression of Flt3L is an
added safety feature of the treatment, and allows us to turn
‘‘on’’ and ‘‘off’’ gene expression upon the addition or with-
drawal of DOX, respectively (Candolfi et al., 2006; Xiong
et al., 2006; Curtin et al., 2008b). In addition, the use of HC-
Ads is expected to reduce the generation of anti-Ad anti-
bodies; this may simultaneously improve efficacy and safety.
DOX is typically used in humans as an antibiotic to treat
various types of infections (DRUGDEX, 2012). When testing the
therapeutic efficacy of HC-Ad-TK+HC-Ad-TetOn-Flt3L in the
preclinical studies, DOX was administered in rat chow at a
concentration of 1,000 parts per million (ppm). Robust protein
expression of Flt3L in brain tissue was shown using both ELISA
and immunostaining in these studies; our data also showed
high therapeutic efficacy and safety of the HC-Ad-mediated
gene therapy approach (Muhammad et al., 2010, 2012).
Despite the safety and accepted use of DOX as an antibi-
otic to treat infections in patients, the use of DOX to activate
gene transcription from the TetOn regulatable promoter
system is not yet approved for use in humans. Thus, this
would be an ‘‘off-label’’ use for this drug. Therefore, as re-
quested by the U.S. Food and Drug Administration (FDA)
before the phase I clinical trial, we assessed the dosage, route
of delivery, and schedule of DOX administration that are
required to turn on Flt3L expression from the TetOn pro-
moter system encoded within HC-Ads in rodents. We
demonstrate here that allometrically scaled doses of DOX,
that is, equivalent doses recommended for use in humans to
treat infections, can safely turn on Flt3L expression from the
HC-Ad-TetOn-Flt3L vector in rodents. We conclude that our
data warrant the use of DOX at doses that have been pre-
viously approved by the FDA to treat infections in humans
in an off-label application of this drug for the treatment of
GBM grade IV in human patients undergoing clinical trials
using HC-Ad-TK +HC-Ad-TetOn-Flt3L gene therapy. Fur-
ther, these data will be of high interest to other researchers
aiming to implement TetOn-dependent therapeutic trans-
gene expression within the central nervous system for the
treatment of other neurological disorders.
Results and Discussion
Clinical trial
Malignant gliomas (GBM) have a very poor prognosis with
a median survival that is measured in months rather than
years (Wen and Kesari, 2008; Grossman et al., 2010). Such an
abysmal disease prognosis compels novel therapeutic ap-
proaches. We propose that the combination approach incor-
porating the crucial immune-stimulating component through
HC-Ad-mediated gene transfer (i.e., Flt3L) will provide the
next advancement in the development of an effective treat-
ment for GBM. In our combined approach, the HSV1-TK does
not play the pivotal role, as its aim is to kill sufficient tumor
cells to provide tumor antigens for incoming immune cells
(Curtin et al., 2009). The pivotal role of our approach is played
by Flt3L, which we have shown in many different models to
recruit antigen presenting immune cells to the brain (Curtin
et al., 2006, 2008a, 2009). The primary objective of the phase I
trial will be to evaluate a range of doses and identify a max-
imum tolerated dose (MTD) of HC-Ad-TK+HC-Ad-TetOn-
Flt3L when administered into the peritumoral region of
resected malignant gliomas (GBM WHO grade IV). The sec-
ondary objective will be to determine early therapeutic ben-
efits of HC-Ad-TK+HC-Ad-TetOn-Flt3L gene therapy in
primary malignant glioma patients. The subject population
will comprise 18 evaluable adult male and female subjects
with malignant gliomas who in the opinion of the clinical
investigator are candidates for surgical treatment and who
meet all inclusion and exclusion criteria defined for this trial
(Supplementary Table S1; Supplementary Data are available
online at www.liebertonline.com/humc) to be treated in one
of five escalating dose cohorts.
As study agents, two HC-Ad vectors will be used; each
vector will encode one therapeutic transgene. Both vectors
are human serotype 5, replication-defective, high-capacity,
helper-dependent adenoviral vectors deleted in all viral
genes with the exception of the viral packaging sequences.
HC-Ad-TK expresses herpes-simplex thymidine kinase un-
der the constitutive mouse cytomegalovirus promoter; when
administered together with the oral prodrug valacyclovir,
highly proliferating tumor cells are preferentially killed. The
other vector, HC-Ad-TetOn-Flt3L, expresses human soluble
Flt3L under the control of the DOX-inducible rtTA2SM2/
tTSKid promoter system; transcription of the immuno-
stimulatory Flt3L is turned on with oral administration of
DOX (Candolfi et al., 2006; Xiong et al., 2006; Curtin et al.,
2008b; Muhammad et al., 2010, 2012).
Both HC-Ad vectors will be manufactured at the vector
production facility at Baylor College of Medicine Center for
Cell and Gene Therapy. The HC-Ad vector particles will be
formulated in 20mM Tris/25mM sodium chloride/2.5%
glycerol (w/w) (pH 8.0). For dose levels requiring dilution
before administration, the vialed product will be diluted
with sterile saline by the hospital pharmacist.
As the prodrug for the TK cytotoxic vector, patients will
be treated with valacyclovir, which has received marketing
approval by FDA as an orally administered antiherpetic
drug (FDA-NDA#020487, 2010; Baker, 1999; Tyring et al.,
2012). Valacyclovir is a valine-ester of acyclovir that is quickly
converted to acyclovir by first-pass intestinal and/or hepatic
metabolism. Clinical studies comparing intravenous acyclovir
to oral valacyclovir delivery have shown that 10mg/kg of
intravenous acyclovir given over 1 hr every 8hr and 2g of
valacyclovir given every 8hr have a similar concentration over
time profile as acyclovir (AUC; hr-lg/ml) (Aguilar-Cordova,
2001). On the basis of the data from this study, this protocol
will use a dose of 2g three times daily for 14 days.
For transcription activation of Flt3L from the inducible
TetOn promoter system, DOX will be administered orally.
DOX is approved for the treatment of a number of different
types of bacterial infections. The typical dose is 100mg/day,
but 200 or 300mg/day is also indicated for more serious
infections. For the clinical trial, we will propose to use a DOX
dose of 200mg/day for 1 month. A brief overview of the
treatment plan follows: subjects meeting all inclusion and
exclusion criteria (Supplementary Table S1) and providing
informed consent will be enrolled in the sequential dosing
cohorts. This protocol will be structured as a dose escalation
study of HC-Ad-TK +HC-Ad-TetOn-Flt3L administered at
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the time of surgery after the tumor has been resected. The
oral prodrug, valacyclovir, will be started 1–3 days after
vector administration, and continued for 14 days. DOX will
also be delivered orally, twice a day, and continued for 1
month. Temozolomide (Temodar) will begin 15–17 days after
surgery and administered at 75mg/m2 daily for 42 days
concomitant with focal radiotherapy (60 Gy administered in
30 fractions) followed by maintenance Temodar for 12 cycles.
Intensive prospective safety monitoring will take place.
Systematic clinical assessments will occur over a 24-month
period postoperatively. The experimental cohorts will be as
follows—cohort 1: 1 · 1010 viral particles (vp) HC-Ad-TK;
cohort 2: 1· 1010 vp HC-Ad-TK + 1· 109 vp HC-Ad-TetOn-
Flt3L; cohort 3: 1· 1011 vp HC-Ad-TK + 1· 109 vp HC-Ad-
TetOn-Flt3L; cohort 4: 1· 1011 vp HC-Ad-TK + 1· 1010 vp
HC-Ad-TetOn-Flt3L; cohort 5: 1 · 1011 vp HC-Ad-TK + 1 ·
1011 vp HC-Ad-TetOn-Flt3L. The first patient will be as-
signed to the first dose (TK alone), and the dose for all future
patients will be sequentially determined from the TITE-CRM
algorithm (Cheung and Chappell, 2000; Zhao et al., 2011);
MTD will be determined after 15 patients are observed. The
TITE-CRM method assumes a model for the time of occur-
rence of a toxic response as a function of dose, and allows
information from all patients enrolled in the trial to be
employed when allocating a new patient to a dose level.
Subjects will be continuously recruited throughout the trial—
without recruitment pauses—as long as patients are treated
at a dose consistent with the current safety profile. It has
been shown that TITE-CRM designs are more efficient
(Goodman et al., 1995; Normolle and Lawrence, 2006; Zhao
et al., 2011) than traditional 3 + 3 designs. They identify MTD
more accurately and provide phase II information, but do
not expose patients to additional risk.
For the surgical procedure, a craniotomy with resection of
the tumor will be performed. At the neurosurgeon’s discre-
tion, this may involve stereotactic methods and/or in-
traoperative navigational guidance and/or intraoperative
magnetic resonance imaging or other radiologic guidance.
Tumor resection will be performed per routine. After the
tumor resection has been completed and adequate hemo-
stasis obtained, two tuberculin syringes will be used to de-
liver the HC-Ad-TK +HC-Ad-TetOn-Flt3L vectors in 100 ll
at each of 20 sites (the total volume infused will be 2ml). The
assignment of dosages will have been determined preoper-
atively as per protocol. Injections will take place over 2min
for each syringe. The vectors will be brought from the
pharmacy in sterile vials, and the filling of the syringes will
occur on a sterile table next to the main operating room table.
If needed, each vial and/or syringe could be filled with an
additional volume of sterile, preservative-free saline to bring
up the volume to 100 ll/site. The vials will not be in the
operating room at room temperature for more than 4 hr be-
fore use. The injection sites will be selected by the surgeon to
avoid injections into adjacent motor or speech cortex, the
cerebral ventricle, or seepage into the subarachnoid space.
After the injections are complete, the needle will be slowly
withdrawn, and the remainder of the surgery will consist of
routine wound closure. Staples will not be used because of
interference with subsequent radiation therapy. It is expected
that the delivery of the viral vectors will require an addi-
tional 40min to the time of surgery. It is expected that each
subject will stay up to four nights in the hospital after sur-
gery. Before discharge, the subject must be independent at
baseline (preoperative status) to be able to walk, speak, and
go to the bathroom. If the patient does not meet the afore-
mentioned criteria, yet he/she is stable from a cardiopul-
monary standpoint, the subject will be discharged to a
rehabilitation facility. Chemotherapy and radiation therapy
will be performed according to current clinical practice
(Stupp et al., 2005, 2007).
The primary objective of this phase I trial is to evaluate the
safety and tolerability of intratumor cavity HC-Ad-mediated
gene therapy as assessed by adverse events, laboratory safety
parameters, general physical/neurological examination, and
the presence of circulating antiadenovirus antibodies. Toxi-
city will be assessed and graded by the NCI Common Ter-
minology Criteria for Adverse Events v4.0 (http://
evs.nci.nih.gov/ftp1/CTCAE/About.html). Once the MTD
is determined, or after all subjects have been evaluated and
found to tolerate the highest dose, the phase 1 study will end
and the results will be reviewed. The appropriate dose for a
future phase 2 study will be the highest administered dose or
MTD from this study. The clinical and tumor responses will
include the following: functional status, medication log,
medical and neurological examinations, magnetic resonance
imaging, survival from date of operation, survival with re-
spect to pre-existing neutralizing anti-adenovirus antibodies,
and progression-free survival. Ad-hCMV-TK with concomi-
tant valacyclovir administration in various cancers has been
well tolerated in previous and ongoing clinical trials using
the same dosages that will be evaluated in this study. Ad-
ditionally, the use of the HC-Ad virus is expected to further
decrease the toxicity to the scaffolding of the normal brain
parenchyma as seen in myriad animal models. Results from
previous and on-going clinical studies in various cancers
with Ad-hCMV-TK followed by valacyclovir indicate that
the treatment is well tolerated within the dose range to be
evaluated in this study, and has been associated with mini-
mal discomfort. In addition, there have been reports of par-
tial responses in some patients (Sandmair et al., 2000;
Immonen et al., 2004; Chiocca et al., 2011). The standard of
care for the patients who are eligible for this protocol will not
be altered by their participation in receiving this experi-
mental therapy. On the basis of the collective body of in-
formation gleaned from nonclinical and clinical studies with
very similar approaches, the expectation is that there will be
minimal risk for the individual patients participating in this
protocol.
Objectives and study design
The primary objective of the present work was to evaluate
whether allometrically scaled doses of DOX are able to ac-
tivate Flt3L gene expression from the HC-Ad-TetOn-Flt3L in
rat brains. Safety assessments, including complete blood
count, serum biochemistry, neuropathology, and circulating
neutralizing antibody titer, were included as secondary
outcomes of the study. To assess if DOX doses previously
used by us (Muhammad et al., 2010) were compatible with
the FDA-approved doses of DOX used in the clinic to treat
infections in humans, we performed a feeding trial (Fig. 1).
The aim was to determine the amount of DOX consumed by
rats when given ad libitum access to 1,000 ppm DOX-con-
taining chow (Fig. 1C). Rats were given free access to DOX
118 VANDERVEEN ET AL.
chow for 2 weeks, and the amount of DOX consumed per rat
was calculated (Fig. 1D). We determined that the previously
used dose of DOX to turn on transgene expression in Lewis
rats in vivo was higher than the levels approved for treating
infections in humans. Thus, to progress toward the clinical
implementation of this combined gene therapy in a phase I
clinical trial for GBM, it was critical to determine whether al-
lometrically scaled doses of DOX were able to induce robust
Flt3L expression in the brain. To this end, HC-Ad-TetOn-Flt3L
vector was injected into the striatum of naı¨ve Lewis rats, and
30.8 or 46.2mg/kg/day of DOX was administered by oral
gavage for 2 weeks. Tissues were harvested at the end of the
study for Flt3L expression, neuropathology, neutralizing an-
tibody titer, and serum chemistry; a schematic of the experi-
mental design is shown in Fig. 2A.
Summary of data
Feeding trial in Lewis rats. To address the need to de-
velop novel therapeutics for GBM, we tested the efficacy and
safety of a combined high-capacity adenoviral gene transfer
therapy, HC-Ad-TK +HC-Ad-TetOn-Flt3L, in preclinical
FIG. 1. Feeding trial in male Le-
wis rats consuming DOX chow. Six
male Lewis rats were housed three
to a cage (two cages total) and were
fed DOX chow for 2 weeks ad libi-
tum, while the daily weight of each
animal (A) was measured. (B) DOX
chow consumption per cage was
also measured. (C) DOX concen-
tration in the rat chow (TestDiet,
cat. no. 5001) was determined at the
University of Michigan College of
Pharmacy Pharmacokinetics Core
facility using a liquid chromatog-
raphy and dual-mass spectrometry
(LC-MS/MS) system; samples were
tested upon arrival (0 months in
storage), and after being refriger-
ated for 3 months (3 months in
storage). (D) Using the aforemen-
tioned data, we were able to calcu-
late the average chow intake/rat/
day to then determine the amount
of DOX that rats undergoing the
preclinical testing consumed (mg/
kg/day). DOX, doxycycline.
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studies (Muhammad et al., 2010, 2012). The therapy com-
bines the use of HSV1-TK+ganciclovir, a conditional cyto-
toxic paradigm to induce tumor cell killing with the induction
of immune stimulation elicited by HC-Ad-mediated Flt3L
expression within the tumor microenvironment (Ali et al.,
2004, 2005). This combined gene therapy strategy results in
tumor regression and the induction of an antitumor immune
response (Curtin et al., 2006; King et al., 2008a, 2008b, 2011;
Ghulam Muhammad et al., 2009; Muhammad et al., 2010). As
an added safety feature, the expression of Flt3L is under the
control of the TetOn regulatable promoter system (Xiong
et al., 2006, 2008), in which Flt3L transcription is turned on
in the presence of DOX and is turned off in the absence of
DOX (Muhammad et al., 2010).
FIG. 2. Determination of effective dose of DOX to turn on therapeutic transgene expression from HC-Ad-TetOn-Flt3L. (A)
Diagram of experimental design used. Adult naı¨ve Lewis rats were injected stereotactically into the right striatum with 1 · 109
viral particles of HC-Ad-TetOn-Flt3L. All rats received DOX or water (control group) via oral gavage twice daily 2 days
before the injection and for 14 days after the injection. One group received 30.80mg/kg/day (low-DOX), while the second
group received 46.20mg/kg/day (high-DOX). The control group received equal volumes of water (No DOX control). Rats
were evaluated 14 days after the injection for circulating levels of anti-adenovirus-neutralizing antibodies in the plasma,
serum biochemistry, circulating DOX levels, transgene expression, and neuropathology. The brains were processed for
immunocytochemistry using primary antibodies against Flt3L to detect expression of the therapeutic transgene in the
striatum. Transgene expression of Flt3L in (B–D) the absence of DOX, (E–G) low-DOX dose of 30.80mg/kg/day (human
equivalent: 200mg), and (H–J) the high-DOX dose of 46.20mg/kg/day (human equivalent: 300mg) are shown within the
striatum of all HC-Ad-injected animals. Scale bar: 1,000lm for full brain sections, 200 lm for 5· images, and 20lm for 40·
images. Flt3L, Fms-like tyrosine kinase 3 ligand; HC-Ad, high-capacity, helper-dependent adenoviral vectors.
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DOX is a broad-spectrum tetracycline antibiotic widely
used to treat infections in humans. The typical dosing regime
is 200mg on the first day followed by 100mg/day (Vi-
bramycin product labeling, Pfizer; Monodox product label-
ing, Aqua Pharmaceuticals), while severe infections require
200mg/day. Either as a single dose or continued for 10 days,
300mg/day has also been used. For example, the re-
commended adult treatment regimen for Acinetobacter, acne
vulgaris, bartonellosis, Clostridia, Escherichia coli, and listeri-
osis, among others, is 200mg orally on day 1 followed by
100mg/day. For more severe infections with these organ-
isms, 200mg/day is recommended (DRUGDEX, 2012). Cer-
tain types of serious infections warrant increased dose. For
example, a dose of 200mg DOX/day for 2 months in con-
junction with additional antibiotics is recommended for an-
thrax inhalation (DRUGDEX, 2012). For late latent syphilis,
200mg/day for 1 month is recommended (DRUGDEX,
2012). Doses of 300mg are rare; however, product labeling for
Monodox indicates treatment with 300mg/day for at least 10
days for primary and secondary syphilis, and the DRUGDEX
database occasionally indicates the use of a 300mg dose for
cholera. The dosing duration is typically 7–10 days, but for
some indications the recommended duration is 3–4 weeks or
more. It is important to note that these doses are recommended
for the treatment of infection in humans. The use of DOX to
activate gene transcription from a regulatable TetOn promoter
in a gene therapy clinical trial will therefore constitute off-label
use of DOX. Thus, the FDA required further characterization
related to the use of DOX for this purpose.
Preclinical studies using tumor-bearing male Lewis rats
have shown that the combined HC-Ad therapy can effec-
tively and safely treat an intracranial, syngeneic model of
glioma (Muhammad et al., 2010, 2012). In these previously
published studies, DOX was administered ad libitum orally in
rat chow. In preparation for a phase I clinical trial for GBM, it
will be important to estimate the DOX dose necessary to turn
on Flt3L expression in humans, and assess if this dose is
compatible to doses of DOX currently used to treat infections
in humans. The use of DOX to turn on therapeutic gene
expression from HC-Ad-TetOn-Flt3L will be an off-label use
of this drug. In response to FDA requirements to enable fil-
ing of an Investigational New Drug for this approach, we
needed to determine the dose of DOX that would turn on
therapeutic transgene expression for the HC-Ad-TetOn-Flt3L
and assess if the required DOX doses would be compatible to
the currently used doses of DOX in humans. To this end, we
performed a feeding trial with DOX chow in male Lewis rats
to quantify the average amount of DOX consumed by each
rat per day. (See Supplementary Materials and Methods.)
The results of the 2-week trial are shown in Fig. 1. Figure 1A
shows that the average weight of the rats (n= 6) increased
from approximately 310 to 350 g over the course of the trial.
Figure 1B shows the chow intake on each day, which re-
mained relatively constant over the 2-week period. Using the
estimated value of 1,000 ppm for the DOX concentration in
the rat chow (Fig. 1C) and an average chow intake of
22.76 g/day (Fig. 1D), we calculated the average rat daily
DOX intake to be 68.52mg/kg/day over the course of the
study ([22.76mg/day]/0.330 kg= 68.52mg/kg/day).
DOX-mediated Flt3L expression after HC-Ad-TetOn-Flt3L
injection. To compare the dose of DOX previously used in
the rodent preclinical efficacy and safety data of the HC-Ad-
mediated gene therapy approach with the doses of DOX
administered to humans to treat infections, we converted the
rat DOX dose to a human dose by dividing the rat dose of
DOX by the allometric conversion factor, that is, 7 (Voisin
et al., 1990), and multiplying by 45.45 kg, an accepted mini-
mum weight for an adult human (DRUGDEX, 2012). This
resulted in an estimated human dose of 445mg/day. Since
FIG. 3. Neuropathological analy-
sis after injection with HC-Ad-Te-
tOn-Flt3L is shown after 14 days of
low-DOX (30.80mg/kg/day) treat-
ment. The brains were processed for
NISSL staining to show gross mor-
phology (A–C), and immunocyto-
chemistry using primary antibodies
against TH to label striatal dopa-
minergic fibers (D–F), and MBP to
label oligodendrocytes and myelin
sheaths (G–I). Scale bar: 1,000lm
for full brain sections, 200lm for
5 · images, and 20lm for 40 · im-
ages. MBP, myelin basic protein;
TH, tyrosine hydroxylase.
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this DOX dose is higher than the dose typically used to treat
infections in humans, we performed an additional study in
rats to assess whether Flt3L can be expressed from the HC-
Ad-TetOn-Flt3L vector using DOX doses allometrically
equivalent to those currently used in humans.
In humans, a typical dose of DOX administered for in-
fections is 100mg/day; however, for more serious infections,
200mg/day, or even 300mg/day, may be recommended
(DRUGDEX, 2012). Therefore, we performed a study to as-
sess Flt3L transgene expression in rats orally gavaged with
DOX doses allometrically equivalent to two of the doses
used in humans, that is, 200 and 300mg/day.
To do this, we allometrically converted the two human
doses for rats using the human-to-rat conversion factor of 7
(Voisin et al., 1990). Assuming a human weight of 45.45 kg, an
accepted minimum weight for an adult human (DRUGDEX,
2012), we calculated the 200mg/day human dose to be
equivalent to a rat dose of 30.8mg/kg/day (low-DOX group).
Similarly, we calculated the 300mg/day human dose to be
equivalent to a rat dose of 46.2mg/kg/day ([(300mg/day)/
45.45kg]·7= 46.2mg/kg/day: high-DOX group). As shown
in the study timeline in Fig. 2A, these two doses of DOX were
administered to male Lewis rats via oral gavage starting on
day -2 and lasting until day 14. The HC-Ad-TetOn-Flt3L
vector containing the DOX-inducible Flt3L gene was injected
into the striatum on day 0. On the final day of the experiment,
day 14, the rats were transcardially perfused with Tyrode’s
solution and fixed with 4% paraformaldehyde. To assess Flt3L
expression, we performed immunohistochemistry on free-float-
ing fixed brain sections. As shown in Fig. 2E–G and Fig. 2H–J,
robust Flt3L expression was observed in both the low-DOX and
the high-DOX groups, respectively, compared with the no DOX
control, which showed no expression of Flt3L (Fig. 2B–D). These
data suggest that the allometrically equivalent human doseswill
be able to activate Flt3L expression in the clinical setting with
doses currently used to treat bacterial infections.
Neuropathology analysis. To investigate the effects of
HC-Ad-TetOn-Flt3L injection and DOX administration on the
architecture and immune cellular infiltrates in the low DOX
groups (Fig. 3 and Fig. 4) and the high DOX groups (Fig. 5
and Fig 6) within the brain, we performed a detailed neuro-
pathology analysis of brain sections at the end of the study. In
the no-DOX control (Supplementary Fig. S1A–C), the low-DOX
(Fig. 3A–C), and the high-DOX (Fig. 5A–C) groups, NISSL
staining demonstrated largely unaffected gross tissue morphol-
ogy with an area of increased cell density near the needle track.
Immunostaining for tyrosine hydroxylase (Supplementary Fig.
S1D–F, Fig. 3D–F, and Fig. 5D–F), indicative of dopaminergic
nerve terminals, showed no gross morphological changes; de-
creased staining intensity was present in the vicinity of the
needle track. Immunostaining for myelin basic protein (Sup-
plementary Fig. S1G–I, Fig. 3G–I, and Fig. 5G–I), which indicates
myelinated axons, also showed no gross morphological changes.
FIG. 4. Immune cellular in-
filtrates after injection with
HC-Ad-TetOn-Flt3L are shown
after 14 days of low-DOX
(30.80mg/kg/day) treatment.
The brainswereprocessedwith
immunocytochemistry using
primary antibodies against
ED1 for labeling macrophages
and activated microglia (A–C),
CD8+T cells (D–F), MHC-II to
label MHC-II+macrophages,
microglia, and immune cells
(G–I), and IBA1 to label acti-
vated macrophages and mi-
croglia ( J–L). Scale bar:
1,000lm for full brain sections,
200lm for 5· images, and
20lm for 40· images.
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Immune cellular infiltrates were present in the no-DOX
control, the low-DOX, and the high-DOX groups surrounding
the injection site. Immunostaining for ED1 (Supplementary
Fig. S1J–L, Fig. 4A–C, and Fig. 6A–C), which is a marker for
activated macrophages, microglia, and monocytes, showed
immunoreactive cells in the vicinity of the injection site. Im-
munostaining for CD8+ T-cells (Supplementary Fig. S1M–O,
Fig. 4D–E, and Fig. 6D–E) showed cellular infiltration near the
injection site, as did immunostaining for MHC-II (Supple-
mentary Fig. S1P–R, Fig. 4G–I, and Fig. 6G–I), a marker of
antigen presenting cells, and IBA1 (Supplementary Fig. S1S–U,
Fig. 4J–L, and Fig. 6J–L), which is a marker for activated
microglia. As shown in Figs. 4 and 6, CD8+ staining and
IBA1 + staining were less intense in the low-DOX group
compared with the high-DOX group, with even less staining
in the no-DOX control group (Supplementary Fig. S1). Im-
mune cells were occasionally observed along the lining of the
ventricles, but no positive staining for ED1, CD8, MHC-II, or
IBA1 was present in the contralateral hemisphere. There was
no loss of tissue or enlargement of the ventricles in either
group, confirming the safety of the HC-Ad-TetOn-Flt3L vector
in the presence of the two doses of DOX tested in this study.
Circulating neutralizing antiadenovirus antibodies. To
measure the levels of circulating neutralizing adenovirus
antibodies (NAABs), blood was collected from each animal
during euthanasia via cardiac puncture (see Supplementary
Materials and Methods). Antibody titers of 64 or below were
considered negative, and titers of 128 or above were con-
sidered positive (Nwanegbo et al., 2004; Puntel et al., 2013).
As shown in Supplementary Fig. S2, the results demonstrate
that plasma levels of NAABs in both the low-DOX and the
high-DOX groups were similar to that found in the saline-
injected control group, and all were below the positive-titer
threshold of 128. This indicates that the HC-Ad vectors de-
livered into the brain parenchyma do not induce a systemic
immune response to the Ad capsid.
DOX concentration in rat plasma. Analysis of the rat
plasma after 2 weeks of DOX administration showed a DOX
concentration in the low-DOX treated group of 1.27–0.295mg/
liter (mean–SEM) and a DOX concentration of 3.06–0.254mg/
liter in the high-DOX treated group (see Supplementary Ma-
terials and Methods, Supplementary Table S1). These levels are
comparable to those measured in humans. Product labeling
for Vibramycin capsules notes that after a 200mg oral dose
of DOX, normal adults had an average serum concentration
of 2.6mg/liter after 2 hr and 1.5mg/liter after 24 hr. Product
labeling for another formulation, Monodox, cites an average
maximum serum concentration of 3.61– 0.18mg/liter ap-
proximately 2.6hr after a 200mg DOX dose. In a review of
studies examining the plasma pharmacokinetics of DOX after
a 200mg single dose, maximum concentration of 5mg/liter
has been measured (Agwuh and MacGowan, 2006). These
data suggest that the plasma DOX concentrations achieved
with DOX doses currently approved for treating infections in
humans are compatible with DOX levels required to achieve
therapeutic transgene expression from HC-Ad-TetON-Flt3L.
Analysis of clinical laboratory parameters. To evaluate
any potential systemic toxicity, we measured several clinical
parameters in the plasma, including indicators of renal and
liver function (see Supplementary Materials and Methods,
Supplementary Table S2). Both the low-DOX and the high-DOX
groups were shown to have normal liver and renal parameters
with respect to naı¨ve Lewis rats, although ALT (alanine ami-
notransferase) levels were slightly elevated in both the low-
DOX and the high-DOX groups. Normal renal function was
FIG. 5. Neuropathological
analysis after injection with
HC-Ad-TetOn-Flt3L is shown
after 14 days of high-DOX
(46.20mg/kg/day) treatment.
The brains were processed for
NISSL staining to show gross
morphology (A–C), and im-
munocytochemistry using pri-
mary antibodies against TH to
label striatal dopaminergic fi-
bers (D–F), and MBP to label
oligodendrocytes and myelin
sheaths (G–I). Scale bar:
1,000 lm for full brain sec-
tions, 200lm for 5 · images,
and 20 lm for 40· images.
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confirmed with analysis of blood urea nitrogen (BUN), creati-
nine (CRE), and albumin (ALB). These results on the safety of
the HC-Ad therapy with DOX administration are consis-
tent with those demonstrated in other studies by our group
(Muhammad et al., 2010, 2012).
An issue related to the off-label use of DOX to activate
Flt3L expression in glioma patients is to assess its safety
profile at the doses required to turn on therapeutic Flt3L gene
expression. In this respect, the safety of DOX in humans has
been studied previously. A pharmacology and toxicology
study for a previously marketed DOX product (Periostat;
NDA # 50-744) tested increasing doses of DOX in rats. In a 2-
week study in rats that used DOX doses ranging from 50 to
400mg/kg/day, which included analysis of food intake,
body weight, clinical symptoms, organs, and organ weights,
slight side effects, including excess salivation and reduced
food intake, were seen only in the highest dose group of
400mg/kg/day. In line with these data, we show in the
present report that Flt3L can be expressed at both 30.8 and
46.2mg/kg/day of DOX with no signs of toxicity; these two
DOX doses are well below the 400mg/kg/day dose identi-
fied as toxic in the Periostat toxicology review.
Conclusions
In the present study, we show that Flt3L is expressed in rat
brain tissue using allometrically scaled doses of DOX
equivalent to those recommended to treat infections in hu-
mans. Importantly, the DOX concentrations in rat plasma
measured in this study are quantitatively similar to those
seen in human serum after treatment using a 200mg dose of
DOX in adults. In this study, no toxicities were observed in
either the low-DOX or the high-DOX treatment groups both
within the central nervous system or systemically. In con-
clusion, this report supports the off-label use of DOX to turn
on FLt3L gene expression after injection of HC-Ad-TetOn-
Flt3L into the tumor cavity in human glioma patients. These
data will be of critical importance for the Investigational
New Drug filing to the FDA in order to enable the clinical
implementation of the combined HC-Ad-mediated gene
therapy strategy to treat GBM in a phase I clinical trial.
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